COMP <GO>
DYAI vs JSPR // EV/EBITDA & P/E VALUATION
Dyadic International Inc. (NASDAQ) VS. Jasper Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DYAI 0
— JSPR 2
■ METRIC PARITY
LAST: $0.36 (-8.40%) • MKT CAP: $14.5M
valuation
—
LAST: $0.53 (-1.26%) • MKT CAP: $17.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DYAI VS. JSPR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DYAI | JSPR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 24.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -11.60% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.7 | 44.3 | -5.67 | JSPR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.5M | $17.7M | -$3.2M | JSPR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DYAI REV | JSPR REV | DYAI GROSS % | JSPR GROSS % | DYAI FCF | JSPR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.1M | $0 | 24.9% | — | -$5.7M | -$77.2M |
| FY 2024 | $3.5M | $0 | 65.8% | — | -$4.0M | -$62.6M |
| FY 2023 | $2.9M | $0 | — | — | -$6.7M | -$52.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DYAI // BETA —
JSPR // BETA —